+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

Orexin Receptor (Hypocretin Receptor) Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Orexin Receptor (Hypocretin Receptor) Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Alpha-2 Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Alpha-2 Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Cannabinoid Receptor Type 1 (CB1) Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Cannabinoid Receptor Type 1 (CB1) Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
GABAB Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

GABAB Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
5-HT1B Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

5-HT1B Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Alpha Receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Alpha Receptor Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Endothelin Receptor A (ETA) Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Endothelin Receptor A (ETA) Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Cannabinoid Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Cannabinoid Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Cannabinoid Receptor Type 2 (CB2) Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Cannabinoid Receptor Type 2 (CB2) Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Mitochondrial Electron Transport Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Mitochondrial Electron Transport Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Prostaglandin D2 receptor Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Prostaglandin D2 receptor Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
5-HT1D Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

5-HT1D Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Alpha v Beta 5 Integrin Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Alpha v Beta 5 Integrin Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
D1 Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

D1 Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
PPAR-Beta / Delta Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

PPAR-Beta / Delta Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
5-HT2C Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

5-HT2C Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
D2 Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

D2 Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Muscarinic Acetylcholine Receptor M2 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Muscarinic Acetylcholine Receptor M2 Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
mGlu5 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

mGlu5 Antagonist - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Muscarinic Acetylcholine Receptor M3 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Muscarinic Acetylcholine Receptor M3 Antagonist - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more